Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | CA4 | P22748 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | POU5F1 | Q01860 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famotidine SCHEMBL39237 | 1.00 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL29384901 | 1.00 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL458654 | 1.00 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28032679 | 0.99 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863201 | 0.99 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL22127098 | 0.99 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863206 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL7119657 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28528271 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL9817308 | 0.98 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32653 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | POLYAMYNA NANOTECH INC. (CA) | 2026-05-28 | — | — | US | claimed |
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-12629422-B2 | Agave syrup formulation or suspension for active pharmaceutical agents | GENEXA INC. (US) | 2026-05-19 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026102141-A1 | COMPOSITIONS FOR PCSK9 GENE EDITING AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| US-4757060-A | Analgesic, H1, H2 receptor blockers | BRISTOL-MYERS COMPANY (US) | 1988-07-12 | — | — | US | claimed |
| EP-0256747-A1 | Morphologically homogenous forms of famotidine and processes for their preparation | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1988-02-24 | — | — | EP | claimed |
| US-4673677-A | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE | PFIZER INC. (US) | 1987-06-16 | — | — | US | claimed |
| CN-86105909-A | The method for preparing N-sulphonamide-3-(2-guanidine radicals-thiazole-4-base-methylthio group)-third amidine | — | 1987-05-13 | — | — | CN | claimed |
| EP-0215639-A2 | Propionamidine derivatives | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1987-03-25 | — | — | EP | claimed |
| EP-0128736-B1 | NOVEL 2-GUANIDINOTHIAZOLINE COMPOUNDS, THEIR PREPARATION, AND THEIR USE AS INTERMEDIATES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-02-25 | — | — | EP | claimed |
| US-4609737-A | DIHALOACETONE AND AMIDINOTHIOUREA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-02 | — | — | US | claimed |
| US-4554276-A | ENZYME INHIBITORS, ANTIULCER AGENTS | PFIZER INC. (US) | 1985-11-19 | — | — | US | claimed |
| EP-0138464-A2 | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | claimed |
| EP-0128736-A1 | Novel 2-guanidinothiazoline compounds, their preparation, and their use as intermediates | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-12-19 | — | — | EP | claimed |